Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 21 of the 72 sources its claims cite were checked for support.

Muscle loss and GLP-1R agonists use

Open access

Abstract

Skeletal muscle wasting is a major yet often overlooked determinant of adverse outcomes in diabetes mellitus and obesity. Loss of muscle mass and strength not only impairs mobility and quality of life, but also worsens insulin resistance, accelerates cardiometabolic decline and increases mortality risk. The convergence of chronic inflammation, mitochondrial dysfunction and altered protein metabolism makes individuals with metabolic diseases particularly vulnerable to sarcopenia. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection. However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies. By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy. It further examines preventive and therapeutic strategies to preserve muscle health during pharmacological weight loss, with the ultimate aim of providing clinicians and researchers with practical insights and future directions to maximize the benefits of GLP-1RAs while mitigating the risk of sarcopenia.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes evidence on skeletal muscle loss during GLP-1 receptor agonist therapy in type 2 diabetes and obesity, concluding that lean mass loss is proportional to total weight loss and not clearly disproportionate versus other weight-loss approaches, but clinically meaningful sarcopenia risk remains undefined. It outlines monitoring, protein intake, resistance exercise, and emerging anabolic/anti-catabolic pharmacotherapies to preserve muscle during GLP-1RA treatment.

Key findings

  • In type 2 diabetes, sarcopenia prevalence ranges from 7% to 29%; in obesity with rapid or marked weight reduction, lean mass decline may account for up to 25–30% of total weight loss, while physiological lean loss typically accounts for roughly one-quarter of total weight loss.
  • Trial body-composition data: STEP 1 semaglutide produced mean Δ body weight −14.9%, with ~34% of weight loss as lean mass and mean Δ lean mass −9.7%; SURMOUNT-1 tirzepatide produced mean Δ body weight −21.3%, with ~25% lean mass and mean Δ lean mass −10.9%; SUSTAIN-8 semaglutide produced mean Δ body weight −6%, with ~43% lean mass (calc) and mean Δ lean mass −4.5% (calc). SURPASS-3 MRI showed muscle volume decrease proportional to weight loss, with maintained fat-free muscle volume and improved muscle quality.
  • Observational and meta-analytic evidence: a cross-sectional study of older adults on semaglutide reported 27.7% prevalence of reduced muscle mass; systematic reviews and meta-analyses found no independent detrimental effect on skeletal muscle index beyond expected proportional reductions, and physical performance outcomes were generally maintained.
  • Prevention and pharmacology: recommended protein intake is 1.2–1.6 g/kg adjusted body weight/day, not below 0.4–0.5 g/kg/day, and prolonged intake ≥2 g/kg/day should be avoided; however, only 43% of GLP-1RA users met 1.2 g/kg/day and <10% reached 1.6–2.0 g/kg/day. In the phase II COURAGE trial interim analysis, trevogrumab plus semaglutide reduced lean mass by 3.3% versus 6.5% with semaglutide alone; no pharmacologic agent is standard of care.

Methods

  • Narrative review including all English-language studies on muscle mass loss during GLP-1RA therapy in type 2 diabetes and obesity from major scientific databases and clinical trial registries.
  • Synthesizes epidemiology and mechanisms of muscle loss, preventive and therapeutic strategies, and novel pharmacological approaches, with summary tables of main clinical trials and management strategies.
  • No formal systematic review protocol, search dates, screening process, risk-of-bias assessment, or meta-analysis is reported.

Limitations

  • Stated: the incidence of clinically significant muscle wasting attributable to GLP-1RA therapy remains undefined; trials have focused on weight and metabolic outcomes, lean mass reduction is typically a secondary endpoint, and most available studies lack direct assessments of muscle strength, physical performance, or gait speed.
  • Stated: definitive randomized trials specifically designed to test protein, amino acid, and micronutrient supplementation in this population are lacking; pharmacologic agents lack consistent functional benefits and long-term safety data, and none is standard of care.
  • Evident: as a narrative review, it does not report a systematic search strategy, study selection, quality appraisal, or quantitative synthesis, so conclusions rely on heterogeneous evidence and indirect comparisons.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00592-025-02611-2

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Principal mechanisms of muscles loss associated with GLP-1 receptor agonists treatment and strategies to counterbalance this phenomenon. GLP-1: glucagon-like peptide-1, RAs: receptor agonists; GH: Growth Hormone, IGF-1: insulin-like growth factor-1, mTOR: mammalian target of rapamycin, ActRII: activin type II receptors, SMAD2/3: small mother against decapentaplegic 2/3, SARMs: selective androgen receptor modulators
Fig. 1 Principal mechanisms of muscles loss associated with GLP-1 receptor agonists treatment and strategies to counterbalance this phenomenon. GLP-1: glucagon-like peptide-1, RAs: receptor agonists; GH: Growth Hormone, IGF-1: insulin-like growth factor-1, mTOR: mammalian target of rapamycin, ActRII: activin type II receptors, SMAD2/3: small mother against decapentaplegic 2/3, SARMs: selective androgen receptor modulatorsCC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 0 Not valid · 46 Not checked · 23 Own results and interpretations

45 more claims · 6 with their cited sources checked

Create a free account to see all 83 claims and to verify the 51 references still open.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 74 references

Research works printed but not linked: 1

  1. Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at 61st EASD Annual Meeting 2025, Wien [press release]

Cited by

See all 32

Metadata

Authors
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P.
Affiliations
  • University of Milan (IT)
  • Brigham and Women's Hospital (US)
Corresponding author
Fiorina, Paolo
Venue
Acta Diabetologica
Published
2025-11-07
Volume
63
Issue
2
Pages
333-342
ISSN
  • 0940-5429 (ISSN-L)
  • 1432-5233
OpenAlex
W4415987720
Cited by
31
References
74
Citations by year
2026: 31
FWCI
4.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Diabetologica (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Funders
Ministero dell’Istruzione, dell’Università e della Ricerca (20229ZA2YF)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
sarcopenia, skeletal muscle atrophy, GLP-1 receptor agonists, type 2 diabetes, obesity, lean mass loss, weight loss, insulin resistance, chronic inflammation, mitochondrial dysfunction, muscle protein metabolism, sarcopenia prevention
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Muscle, Skeletal, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Muscle loss and GLP-1R agonists use. https://app.cochat.ai/papers/10.1007/s00592-025-02611-2
The paper
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025). Muscle loss and GLP-1R agonists use. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02611-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.